{
  "docId": "019de077-880d-703f-ad59-c0ee1df8dfeb",
  "docSlug": "3a2edb97bafa9f0a0205c3f0e878214f",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 26 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 26,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a schematic of the CAR-T construct.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/23",
  "deckHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb",
  "deckJsonHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json",
  "deckAnchorHref": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.24
      },
      "kind": "image",
      "text": "Schematic of CAR-T construct",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fc55272-6f10-455c-9317-675ba2fda34e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "list",
      "text": "Clinical Development strategy: POC achieved in IIT with 43 patients enrolled. US IND was cleared on June 1, 2022. Orphan Drug Designation was granted by FDA on November 22, 2022. The US clinical trial is actively recruiting at six sites.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bac49aa-a2a5-416e-8a3c-ea95712004e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "MoA/Scientific Rationale: LB1908 targets CLDN 18.2 via a proprietary VHH antibody. High selectivity against the closely related CLDN 18.1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d738017b-5637-4e1d-869e-4f2417918b41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "TARGET: Claudins (CLDN) are a family of tight junction proteins. CLDN18.2 is expressed in gastric cancer and pancreatic cancer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "feafbfcb-bcb3-4655-9d53-d784548d98f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "For gastric cancer, esophageal cancer and pancreatic cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d87c226-a6ae-4208-abdc-6082be2fdbb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.64,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Zhang J, et al. Chin J Cancer Res. 2020 Apr;32(2):263-70. 2 Sahin U,et al. Clin Cancer Res. 2008 Dec 1;14(23):7624-34",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59dbbb18-4c67-4532-ad06-966699a0b5d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "LB1908 (LCAR-C18S): Legend CAR-T Targeting CLDN18.2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "188bc056-4ea1-47bf-abd6-757a1f812f4b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867",
      "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.",
      "position": 1,
      "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}